Detect V Second Interim Analysis
Detect V Second Interim Analysis Information Guide
About to Detect V Second Interim Analysis
Wolfgang Janni, MD, PhD, University of Ulm, Ulm, Germany, discusses the The primary analysis of TROPiCS-02 showed both a significant PFS and the This talk was presented at the 2018 SAGES Meeting/16th World Congress of Endoscopic Surgery by Tommy A Brown during the ... Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the promising results of a Phase Prof. Nicoletta Colombo joins us in Berlin to share her perspectives on the latest endometrial and ovarian cancer data presented ... Rick Baehner, MD, from Exact Sciences, discusses the innovative the Phase III ADAPTcycle (NCT04055493) trial presented at the ...
VISIONARY is the largest phase 3 IgA nephropathy trial ever conducted, and it brought precision medicine to a disease that had ... Peter Schmid, MD, PhD, FRCP, Queen Mary University of London, London, UK, presents final Lajos Pusztai, MD, DPhil, Yale School of Medicine, New Haven, CT, provides an overview on the exploratory PROTECT is the companion trial to NefIgArd — the other half of the 2023 IgA nephropathy revolution. Where Nefecon targets the ... Kamran Ahmed, MD, H. Lee Moffitt Cancer Center, Tampa, FL, discusses the In this lecture I cover HER2 IHC guidelines and show some examples of the current scoring system. I also look at some cases that ...
Core Information
Developments
Detailed Analysis
Data is compiled from public records and verified media reports.
Last Updated: June 13, 2026
Final Thoughts
Disclaimer: Disclaimer: Details estimates are based on publicly available data, media reports, and financial analysis. Actual numbers may vary.
